How Mounjaro Works — and Why It's Different from Other Weight-Loss Injections

The biggest myth: Mounjaro is just another GLP-1 jab

Most people researching Mounjaro arrive having already read about semaglutide-based injections. The assumption that Mounjaro works the same way is understandable, both are weekly injections, both reduce appetite, both are used for weight management. But the mechanism is genuinely different, and that difference matters.

Semaglutide targets one receptor: GLP-1 (glucagon-like peptide-1). Mounjaro targets two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a gut hormone that plays its own separate role in appetite control, fat metabolism and how cells respond to insulin. Hitting both pathways at once produces a stronger combined signal than either pathway alone could generate.

This isn't a marketing distinction. The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4 mg over 72 weeks in adults with obesity and found tirzepatide produced greater average weight reduction. The NHS Mounjaro medicines page describes it plainly as a dual GIP and GLP-1 receptor agonist, the only one of its kind licensed here. If you want more on the tirzepatide molecule itself, the tirzepatide overview on our site goes deeper into the pharmacology.

So while Mounjaro sits in the same broad family as other weight-loss injections, calling it "just another GLP-1" undersells what's actually happening when you inject it each week.

What the two receptors actually do once activated

When tirzepatide binds to GLP-1 receptors, it mimics the effect of a naturally occurring hormone your gut releases after you eat. Gastric emptying slows (food moves more gradually from stomach to intestine) so you feel full for longer after a smaller meal. Signals reach the brain's appetite-control centres telling you that you've had enough. Blood sugar rises more gradually rather than in a sharp post-meal spike.

The GIP side adds a layer. GIP receptors in fat tissue appear to influence how the body stores and breaks down fat, and GIP signalling in the brain may further reinforce the satiety message. The combined result is that people on Mounjaro typically find their desire to eat reduces substantially, not through willpower, but because the hormonal signals that normally drive hunger are being met and held at bay.

Gastric emptying is also why the weight-loss mechanism has a knock-on effect on eating behaviour beyond just appetite: meals that once felt too small start to feel genuinely sufficient. For a closer look at the jab's physical delivery and what happens step by step after each injection, the guide to how the Mounjaro jab works covers injection sites, the KwikPen format and absorption.

It's worth knowing that gastric slowing is also responsible for the most common side effects: nausea, a sensation of being uncomfortably full, occasional reflux or constipation. These tend to be most noticeable in the early weeks or after a dose increase, and they usually settle as the body adjusts.

The dose schedule and what the starter dose is actually for

Mounjaro comes in six UK strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg, each as a pre-filled KwikPen containing four weekly doses. Treatment begins at 2.5 mg. That opening dose is not where therapeutic weight loss happens for most people, its job is to let your digestive system adapt to the new hormonal signals before the dose steps up.

The prescriber typically increases the dose in 4-week steps, guided by how well you're tolerating the current level. Rushing that process is the wrong approach; the titration schedule is a considered clinical one, set out in the Mounjaro SmPC. Questions about how quickly Mounjaro starts to produce visible results are addressed on the timeline page, the honest answer is that most people notice appetite changes before they see the scales move.

Dose changes and anything about what you personally should take next should always go through your prescriber, not a forum or a general article. If you're already on treatment and wondering about your next step, our aftercare team is available seven days a week.

Eligibility, the prescription process and what comes next

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 and above if at least one weight-related condition is present, for example, high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. For South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance recognises lower BMI thresholds of 2.5 kg/m² across those bands. BMI alone doesn't determine approval; a prescriber weighs the full clinical picture.

NICE recommended tirzepatide for NHS use in December 2024 (TA1026), though NHS eligibility criteria are narrower and access is being phased in gradually. The private route through a regulated pharmacy means no referral and no waiting list, provided you meet the clinical criteria. Every order placed with a regulated online pharmacy should come with a genuine prescription issued after a real clinical review, not software, not a tick-box form reviewed by no one.

At nume, a GPhC-registered Independent Prescriber personally reads every consultation the same day. If you order by midday on a working day and are approved, treatment is dispatched that afternoon and delivered free the next working day by DPD, in plain unbranded packaging. You can verify our pharmacy on the GPhC register (registration number 9012878) at pharmacyregulation.org.

For context on the cost of private treatment, the Mounjaro cost guide explains how UK pricing works and what a legitimate price should include. If you'd like to explore whether treatment is suitable for you, check your eligibility with a free consultation, there's no obligation and no upfront fee.